Vera Therapeutics, Inc. (VERA)
27.99
-1.06
(-3.65%)
USD |
NASDAQ |
Oct 23, 16:00
28.00
+0.01
(+0.04%)
After-Hours: 20:00
Vera Therapeutics Enterprise Value : 1.590B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.590B |
| October 22, 2026 | 1.666B |
| October 21, 2026 | 1.821B |
| October 20, 2026 | 1.739B |
| October 19, 2026 | 1.657B |
| October 16, 2026 | 1.582B |
| October 15, 2026 | 1.632B |
| October 14, 2026 | 1.500B |
| October 13, 2026 | 1.504B |
| October 12, 2026 | 1.571B |
| October 09, 2026 | 1.726B |
| October 08, 2026 | 1.715B |
| October 07, 2026 | 1.753B |
| October 06, 2026 | 1.693B |
| October 05, 2026 | 1.723B |
| October 02, 2026 | 1.765B |
| October 01, 2026 | 1.806B |
| September 30, 2026 | 1.900B |
| September 29, 2026 | 1.906B |
| September 28, 2026 | 1.915B |
| September 25, 2026 | 1.918B |
| September 24, 2026 | 1.975B |
| September 23, 2026 | 1.954B |
| September 22, 2026 | 2.185B |
| September 21, 2026 | 2.041B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.023B |
| September 17, 2026 | 2.042B |
| September 16, 2026 | 1.862B |
| September 15, 2026 | 1.999B |
| September 14, 2026 | 2.026B |
| September 11, 2026 | 2.098B |
| September 10, 2026 | 1.994B |
| September 09, 2026 | 2.007B |
| September 08, 2026 | 2.115B |
| September 04, 2026 | 2.159B |
| September 03, 2026 | 2.094B |
| September 02, 2026 | 2.142B |
| September 01, 2026 | 2.039B |
| August 31, 2026 | 2.028B |
| August 28, 2026 | 2.036B |
| August 27, 2026 | 2.066B |
| August 26, 2026 | 2.225B |
| August 25, 2026 | 2.115B |
| August 24, 2026 | 2.002B |
| August 21, 2026 | 1.898B |
| August 20, 2026 | 1.825B |
| August 19, 2026 | 1.898B |
| August 18, 2026 | 1.899B |
| August 17, 2026 | 1.852B |
| August 14, 2026 | 1.852B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.578B |
| Sarepta Therapeutics, Inc. | 2.130B |
| Twist Bioscience Corp. | 8.696B |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -109.47M |
| Total Expenses (Quarterly) | 109.47M |
| EPS Diluted (Quarterly) | -1.524 |
| Earnings Yield | -20.97% |
| Normalized Earnings Yield | -20.97 |